HUE042763T2 - Módosított szerpinek vérzési rendellenességek kezelésére - Google Patents

Módosított szerpinek vérzési rendellenességek kezelésére

Info

Publication number
HUE042763T2
HUE042763T2 HUE14827185A HUE14827185A HUE042763T2 HU E042763 T2 HUE042763 T2 HU E042763T2 HU E14827185 A HUE14827185 A HU E14827185A HU E14827185 A HUE14827185 A HU E14827185A HU E042763 T2 HUE042763 T2 HU E042763T2
Authority
HU
Hungary
Prior art keywords
treatment
bleeding disorders
modified serpins
serpins
modified
Prior art date
Application number
HUE14827185A
Other languages
English (en)
Hungarian (hu)
Inventor
James Andrew Huntington
Stephanie Polderdijk
Trevor Baglin
Original Assignee
Cambridge Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Entpr Ltd filed Critical Cambridge Entpr Ltd
Publication of HUE042763T2 publication Critical patent/HUE042763T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121Serpins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001Use of materials characterised by their function or physical properties
    • A61L24/0015Medicaments; Biocides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028Polypeptides; Proteins; Degradation products thereof
    • A61L26/0047Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121Serpins
    • C07K14/8125Alpha-1-antitrypsin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/418Agents promoting blood coagulation, blood-clotting agents, embolising agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/04Materials for stopping bleeding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
HUE14827185A 2013-12-13 2014-12-15 Módosított szerpinek vérzési rendellenességek kezelésére HUE042763T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1322091.8A GB201322091D0 (en) 2013-12-13 2013-12-13 Modified serpins for the treatment of bleeding disorders

Publications (1)

Publication Number Publication Date
HUE042763T2 true HUE042763T2 (hu) 2019-07-29

Family

ID=50030900

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14827185A HUE042763T2 (hu) 2013-12-13 2014-12-15 Módosított szerpinek vérzési rendellenességek kezelésére

Country Status (25)

Country Link
US (2) US9982035B2 (https=)
EP (2) EP3434689A1 (https=)
JP (2) JP6431541B2 (https=)
KR (2) KR101954945B1 (https=)
CN (2) CN105992771B (https=)
AU (2) AU2014363359B2 (https=)
CA (1) CA2933508C (https=)
CY (1) CY1121267T1 (https=)
DK (1) DK3080157T3 (https=)
EA (1) EA034050B1 (https=)
ES (1) ES2704058T3 (https=)
GB (1) GB201322091D0 (https=)
HR (1) HRP20182138T1 (https=)
HU (1) HUE042763T2 (https=)
IL (2) IL246180B (https=)
LT (1) LT3080157T (https=)
MX (1) MX357941B (https=)
NZ (1) NZ721918A (https=)
PL (1) PL3080157T3 (https=)
PT (1) PT3080157T (https=)
RS (1) RS58191B1 (https=)
SI (1) SI3080157T1 (https=)
SM (1) SMT201900016T1 (https=)
TR (1) TR201819781T4 (https=)
WO (1) WO2015086854A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045659A1 (en) 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
JP6890831B2 (ja) 2015-07-08 2021-06-18 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Hiv予備免疫化および免疫療法
DK3402483T3 (da) 2016-01-15 2024-01-02 American Gene Tech Int Inc Fremgangsmåder og sammensætninger til aktivering af gamma-delta-T-celler
US10888613B2 (en) 2016-02-08 2021-01-12 American Gene Technologies International Inc. Method of producing cells resistant to HIV infection
DK3426777T3 (da) 2016-03-09 2022-04-25 American Gene Tech Int Inc Kombinationsvektorer og fremgangsmåder til behandling af cancer
US11976292B2 (en) 2016-06-08 2024-05-07 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
IL284348B2 (en) 2016-07-08 2025-06-01 American Gene Tech Int Inc Hiv pre-immunization and immunotherapy
DK3585808T3 (da) * 2017-02-23 2022-01-31 Preclinics Ges Fuer Praeklinische Forschung Mbh Modificerede serpiner til behandlingen af bradykinin formidlet sygdom
CA3057142A1 (en) 2017-04-03 2018-10-11 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
RU2663464C1 (ru) * 2018-02-26 2018-08-06 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Комбинаторная терапия для лечения геморрагического шока
CA3117961A1 (en) * 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders
CN110051830A (zh) * 2019-03-14 2019-07-26 苏州新凝生物医药科技有限公司 一种protease nexin II\KPI蛋白突变体的应用
EP4326869A4 (en) * 2021-04-20 2025-12-10 Univ Of Louisville RECOMBINATING MICRO-NECK
WO2023118150A1 (en) 2021-12-22 2023-06-29 Royal College Of Surgeons In Ireland A conjugate for use in localising a molecule to the vascular endothelium.
EP4707391A1 (en) * 2024-09-10 2026-03-11 e-therapeutics PLC Nucleic acid compounds for zpi inhibition

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711848A (en) 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
FR2599752B1 (fr) 1986-06-10 1989-11-03 Transgene Sa Variants de l'alpha1- antitrypsine utiles notamment comme inhibiteurs de la kallikreine
DE3705745A1 (de) 1987-02-23 1988-09-01 Behringwerke Ag Protein c-inhibitor (pci) als pharmazeutikum und in vitro-diagnostikum, verfahren zur herstellung eines solchen pharmazeutikums oder diagnostikums sowie ein mittel enthaltend pci
US5612194A (en) 1989-06-23 1997-03-18 Trustees Of The University Of Pennsylvania Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors
IE902276A1 (en) 1989-06-26 1991-01-16 Akzo Nv Serpin variants
US6566493B1 (en) 1996-11-19 2003-05-20 The University Of Vermont Peptidomimetics containing 6-peptidylamino-1-naphthalenesulfonamide moieties
WO2001055390A1 (en) 2000-01-28 2001-08-02 Human Genome Sciences, Inc. Human serpin polynucleotides, polypeptides, and antibodies
JP2002010783A (ja) 2000-06-29 2002-01-15 Jcr Pharmaceuticals Co Ltd 改変型ヒトプロテインcインヒビター
US6924267B2 (en) 2001-09-18 2005-08-02 Suomen Punainen Risti Veripalvelu Methods and active substances for protecting organs
JP2003093063A (ja) 2001-09-20 2003-04-02 Jcr Pharmaceuticals Co Ltd 改変型ヒトプロテインcインヒビター
EP1446150A1 (en) 2001-11-09 2004-08-18 Novo Nordisk Health Care AG Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
FR2836143B1 (fr) 2002-02-21 2004-04-16 Servier Lab Nouveaux derives d'acides amines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2508276C (en) 2002-12-05 2018-03-27 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
WO2004056309A2 (en) 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
WO2006090282A2 (en) * 2005-02-28 2006-08-31 Universite De Lausanne Recombinant inhibitor proteins of an hk14 protease and use thereof
US8106002B2 (en) 2005-04-18 2012-01-31 Chugai Seiyaku Kabushiki Kaisha Anti-cancer agent comprising protein C inhibitor
CA3071172A1 (en) * 2005-12-15 2008-04-17 Gulfstream Aerospace Corporation Isentropic compression inlet for supersonic aircraft
KR101778174B1 (ko) 2006-07-05 2017-09-13 카탈리스트 바이오사이언시즈, 인코포레이티드 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
WO2008059043A2 (en) 2006-11-16 2008-05-22 Crucell Holland B.V. Combination of coagulation factor viii with apc-resistant factor v
EP2081589B1 (en) 2006-11-16 2010-10-06 Crucell Holland B.V. Complementation of factor xi deficiency by factor v mutants
WO2008059009A2 (en) 2006-11-16 2008-05-22 Crucell Holland B.V. Factor v mutants for hemostasis in hemophilia
US8741844B2 (en) 2007-07-20 2014-06-03 Universite Paris-Sud Xi Use of mutated antithrombins for treating or preventing coagulation disorders
GB0714649D0 (en) 2007-07-27 2007-09-05 Univ Leuven Kath Novel viral replication inhibitors
JP2011500843A (ja) 2007-10-26 2011-01-06 オクラホマ・メディカル・リサーチ・ファウンデーション 活性化プロテインcおよび不活性化プロテインcに対するモノクロナール抗体
EP2055783A1 (en) * 2007-10-30 2009-05-06 VIB vzw Insect inhibiting plant serpin mutants
CN101965409A (zh) 2007-11-01 2011-02-02 罗切斯特大学 具有增加的稳定性的重组因子viii
CN110522905A (zh) * 2008-01-21 2019-12-03 德莫迪斯公司 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途
CA2749772C (en) 2009-01-16 2018-02-20 Assistance Publique-Hopitaux De Paris Mutated antithrombins, a process for preparing the same and their use as drugs
WO2010123290A2 (ko) * 2009-04-22 2010-10-28 (주)알테오젠 체내 지속성을 유지함으로 체내 반감기가 증가된 단백질 또는 펩티드 융합체, 및 이를 이용하여 체내 반감기를 증가시키는 방법
WO2011123830A2 (en) * 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
EP2996713B1 (en) 2013-05-15 2019-10-02 Mor Research Applications Ltd. Compositions and methods for treating post-operative complications of cardiopulmonary surgery
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
DK3585808T3 (da) * 2017-02-23 2022-01-31 Preclinics Ges Fuer Praeklinische Forschung Mbh Modificerede serpiner til behandlingen af bradykinin formidlet sygdom

Also Published As

Publication number Publication date
SI3080157T1 (sl) 2018-12-31
US20160311887A1 (en) 2016-10-27
EP3080157A1 (en) 2016-10-19
CN105992771A (zh) 2016-10-05
NZ721918A (en) 2019-12-20
IL262879A (en) 2018-12-31
CN110330563A (zh) 2019-10-15
TR201819781T4 (tr) 2019-01-21
PL3080157T3 (pl) 2019-03-29
CY1121267T1 (el) 2020-05-29
KR20190022945A (ko) 2019-03-06
KR101954945B1 (ko) 2019-03-07
JP6431541B2 (ja) 2018-11-28
EA201691235A1 (ru) 2016-12-30
HRP20182138T1 (hr) 2019-02-08
LT3080157T (lt) 2018-12-10
US9982035B2 (en) 2018-05-29
CA2933508C (en) 2021-04-06
IL246180A0 (en) 2016-07-31
AU2014363359A1 (en) 2016-07-21
MX357941B (es) 2018-07-31
DK3080157T3 (en) 2018-12-17
AU2018279054A1 (en) 2019-01-17
CN110330563B (zh) 2024-03-29
ES2704058T3 (es) 2019-03-14
KR102186924B1 (ko) 2020-12-04
IL246180B (en) 2018-11-29
KR20160092025A (ko) 2016-08-03
JP2019037242A (ja) 2019-03-14
WO2015086854A1 (en) 2015-06-18
PT3080157T (pt) 2019-01-11
RS58191B1 (sr) 2019-03-29
US20180273610A1 (en) 2018-09-27
EP3434689A1 (en) 2019-01-30
CA2933508A1 (en) 2015-06-18
EP3080157B1 (en) 2018-10-03
EA034050B1 (ru) 2019-12-23
JP6723319B2 (ja) 2020-07-15
MX2016007711A (es) 2016-12-09
JP2017505114A (ja) 2017-02-16
CN105992771B (zh) 2019-08-23
SMT201900016T1 (it) 2019-02-28
BR112016013591A2 (pt) 2017-10-03
US10351619B2 (en) 2019-07-16
AU2014363359B2 (en) 2019-01-03
GB201322091D0 (en) 2014-01-29

Similar Documents

Publication Publication Date Title
IL283943A (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
CY2021007I1 (el) Συνθεσεις χρησιμες για τη θεραπεια διαταραχων που σχετιζονται με kit
IL262879A (en) Modified seraphins for the treatment of bleeding disorders
IL268987B (en) System for glaucoma treatment
LT2984166T (lt) Kompozicijos, skirtos mpsi gydymui
HUE061618T2 (hu) Vegyület szemrendellenességek kezelésére
PL3010910T3 (pl) Związki pirymidynodionu przeciwko chorobom serca
IL243976B (en) kdm1a inhibitors for disease treatment
DK3076967T3 (da) Fremgangsmåder til behandling af residuelle symptomer på skizofreni
LT2981255T (lt) Empagliflozino terapiniai panaudojimo būdai
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
PT3626270T (pt) Tratamento de doenças cardiovasculares
IL256206A (en) Mct4 inhibitors for treating disease
LT3007726T (lt) Tautopatijos gydymo būdai
DK3062811T3 (da) Angiopoietin-baserede interventioner til behandling af cerebral malaria
HUE037179T2 (hu) Gyógyászati kompozíciók izom-rendellenességek kezelésére
CL2016001220A1 (es) Gasa quirurgica
LT3563837T (lt) Terapija bakteriofagu
EP3016944A4 (en) COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS
EP3373875A4 (en) BANDAGE
HRP20181799T1 (hr) Optimizirana farmaceutska formula, namijenjena liječenju upalnih promjena jednjaka
HUE049301T2 (hu) Kurkofenol-vegyület rák kezelésére
SI2986325T1 (sl) Postopki zdravljenja motenj ciklusa sečnine
SMT201800593T1 (it) Inibitore per disturbi retinocoroidei
LT3052625T (lt) Notch 1 specifinės sirnr molekulės